Market Research Industry Reports

Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Macro Analysis

Performance of the Mature Biotech companies recommended by MP Advisors
in 2012 -report card is very impressive and we expect the positive sentiments
to prevail in 2013 and beyond
Valuation Multiples and Fundamentals- Drivers of Growth.
MP Advisors Proprietary Sum-of-The-Parts Valuation and Top Picks for 2013
Drug Approvals 2012-15
Key Milestones During 2013/14
Impact on revenue 2012-2017 from Patent Expiry and Strategies deployed to
meet the challenges.
Pipeline of Biosimilar mAbs
Joint Ventures between innovators and biosimilar players
Merger & Acquisitions Forecast- 2013-2020

In-depth Company Analysis
1. Acorda (ACOR)
1.1. Continuing Growth in AMPYRAs Sales
1.2. Ex. US Sales Risk Factored in the Current Price
1.3. Pipeline Beyond AMPYRA AC105, diazepam
1.4. Takeover target
1.5. Sum of the parts valuation
1.6. Background
2. Alexion (ALXN)
2.1. Product Pipeline Future Potential
2.2. Soliris in PNH and aHUS: Growth to Continue
2.3. Soliris beyond PNH and aHUS
2.4. Diversifying Beyond Soliris - Asfotase alfa, ALXN1102/ALXN1103,
ALXN1007
2.5. Sum of the parts valuation
3. Amgen (AMGN)
3.1. Investment Drivers
3.2. Pipeline Products Promising Progress, AMG145, Romosozumab
3.3. Enriched Pipeline through acquisitions or collaborations -
Blinatumomab, Talimogene laherparepvec, Omecamtiv mecarbil
3.4. Divest Pipeline Products Smartly
3.5. Tapping Emerging markets and other Geographical Expansion
3.6. Strategy for Biosimilars onslaught
3.7. Sum of the parts valuation
3.8. AHA 12 UPDATE: AMG 145 HYPERLIPIDEMIA
3.9. COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB HYPERLIPIDEMIABiogen Idec (BIIB)
4.1. Catalysts in the Next 6-8 Months BG-12, recombinant long-lasting
Factor VIII (rFVIIFc) and IX (rFIXFc), Obinutuzumab
4.2. March of Marketed Products Continues
4.3. Sum of the parts valuation
4.4. OBINUTUZUMAB: PHIII TRIALS
4.5. RITUXIMAB BIOSIMILAR PIPELINE
4.6. Other CNS drugs in the Pipeline
4.7. Biosimilar Development
5. Celgene (CELG)
5.1. Upcoming Key Milestones Pomalidomide, Apremilast, ABRAXANE
5.2. Negative Downside risk but not before 2019
5.3. Sum of the parts valuation
5.4. PROTEASOME INHIBITOR - CLINICAL DATA COMPARISON: R/R
MM
6. Gilead (GILD)
6.1. Advancements in the Anti-viral space HIV and HCV
6.2. Beyond Anti-Virals
6.3. Key Catalysts Sofosubivir, QUAD Pill, Elvitegravir
6.4. Competition from dolutegravir
6.5. Pipeline beyond anti-virals Ranexa, GS-1101 (PI3K inhibitor)
6.6. Sum of the parts valuation
6.7. KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
6.8. DEVELOPMENT PIPELINE
7. Grifols (GRF)
7.1. Basis of OP recommendation
7.2. IVIG AD Opportunity A Wild Card but Not a Risk to its Core Business
7.3. Capacity Matters in Plasma Business
7.4. Weakness
7.5. BACKGROUND - BioScience Division, Diagnostic, Hospital
7.6. NEW PROTEINS IN DEVELOPMENT
7.7. FDA APPROVED PRODUCTS FRACTIONATED PLASMA
PRODUCTS
8. Onyx (ONXX)
8.1. Investments drivers Kyprolis, Oprozomab, Nexavar label expansion
8.2. Sum of the parts valuation
8.3. KYPROLIS: ASH 12 UPDATE
9. Regeneron (REGN)
9.1. Investments drivers
9.2. Upcoming Catalysts Marketed Products (Eylea, ZALTRAP)
9.3. Upside from Ex-Trap Late -stage Pipeline (REGN727/SAR236553,
Sarilumab, REGN475)
9.4. Sum of the parts valuation
9.5. COMPETITIVE LANDSCAPE: ANTI-PCSK9 MAB HYPERLIPIDEMIA
9.6. Commercializing strategy
9.7. Manufacturing and Global Supply Chain:
9.8. VASCEPA vs. LOVAZA & EPANOVA
9.9. CLINICAL DATA COMPARISON IN HYPERTRIGLYCERIDEMIA
VASCEPA vs. LOVAZA & EPANOVAVertex (VRTX)
10.1. INCIVEK, KALYDECO Label Expansion Little to Bet On,
10.2. Development Plans for IFN-free Combination
10.3. Beyond HCV and CF VX-509m VX-787, VX-765
10.4. Sum of the parts valuation
10.5. KEY PIPELINE PRODUCTS: IFN-FREE COMBINATION
10.6. DEVELOPMENT PIPELINE
10.7. DATA FROM IFN-FREE COMBINATIONS

Industry Tables
Valuation Snapshots
Expected Drug Clinical Milestones
MB sector Selected M&A Activities
Marketed Products Potential
Pipeline Potential Thru 2017
Patent Expiry Impact On The Sector
Valuation Snapshots
Expected Drug Clinical Milestones
MB sector Selected M&A Activities
Marketed Products Potential
Pipeline Potential Thru 2017
Patent Expiry Impact On The Sector

List Of Tables

N/A

List Of Figures

Valuation Snapshots
Expected Drug Clinical Milestones
MB sector Selected M&A Activities
Marketed Products Potential
Pipeline Potential Thru 2017
Patent Expiry Impact On The Sector

2018 Global Yersinia Testing Market: US, Europe, Japan--Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

The report presents a detailed analysis of the Yersinia diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Yersinia definition,

USD 4350View Report

2018 Global Vibrio Testing Market: US, Europe, Japan--Sales Segment Forecasts by Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities

The report presents a detailed analysis of the Vibrio diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Vibrio definition,

USD 4350View Report

Global Pharmaceutical Packaging Equipment Market – By Product Type (Solids, Semi-Solids, Liquids), By Package Type (Primary, Secondary, Labeling and Serialization), By Region, By Country: Opportunities and Forecasts (2018-2023)

Executive A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Pharmaceutical Packaging

USD 2400View Report

Global Pharmaceutical Desiccant Market – Trends & Forecast, 2016-2027

Report Description IntroductionAccording to IMS Market prognosis, the U.S. is leading the market in terms of pharmaceutical spending per capita in 2016, followed by Japan and Canada. The government of

USD 4450View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprisewide Licence    USD 7500
$ 2500

Reports Details

Published Date : Jan 2013
No. of Pages :110
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube